Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 13/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vesamicol SCHEMBL571598 | 1.00 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL4499985 | 1.00 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL12648665 | 1.00 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL8984052 | 0.97 | SLC18A3 (0.94) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| Vesamicol SCHEMBL29506749 | 0.89 | SLC18A3 (0.79) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL25405320 | 0.84 | SLC18A3 (0.73) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL29187480 | 0.84 | SLC18A3 (0.73) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL29187479 | 0.84 | SLC18A3 (0.73) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL9980685 | 0.83 | SLC18A3 (0.72) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL11007772 | 0.83 | SLC18A3 (1.00) | SLC18A3CYP2D6TSHRSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
| US-20090005576-A1 | Production Method of Optically Active Cyclohexane Ether Compounds | ASTELLAS PHARMA INC. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-5876694-A | NON-INVASIVELY MAPPING CHOLINERGIC INNERVATION IN A LIVING BRAIN COMPRISES INJECTING THE BRAIN WITH A RADIOLABELLED VESAMICOL DERIVATIVE, MAGNETIC RESONANCE IMAGING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0648130-B1 | RADIOIODINATED BENZOVESAMICOL ANALOGS FOR CHOLINERGIC NERVE MAPPING | UNIV MICHIGAN (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5789420-A | Azavesamicols | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-08-04 | — | — | US | disclosed |
| US-5721243-A | ANTICHOLINERGIC AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-02-24 | — | — | US | disclosed |
| US-5554752-A | SPIRO FUSED PIPERIDINES CAPABLE OF BINDING TO A VESAMICOL RECEPTOR AND HAVING ANTICHOLINERGIC PROPERTIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0576611-A4 | RADIOPHARMACEUTICAL AGENTS FOR THE DETECTION OF ALZHEIMER'S DISEASE | UNIV MINNESOTA (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5457207-A | Anticholinergic agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1995009631-A1 | SPIROVESAMICOLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0643696-A1 | AZAVESAMICOLS | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0643696-A4 | AZAVESAMICOLS. | UNIV MINNESOTA (US) | 1995-01-20 | — | — | EP | disclosed |
| US-5358712-A | For binding to receptors when monitoring for cholinergic innervation in living brains, detection of Alzheimer*s disease | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-10-25 | — | — | US | disclosed |
| US-5338852-A | Azavesamicols | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0576611-A1 | RADIOPHARMACEUTICAL AGENTS FOR THE DETECTION OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1993024457-A1 | AZAVESAMICOLS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1992016239-A1 | RADIOPHARMACEUTICAL AGENTS FOR THE DETECTION OF ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5077035-A | Scintigraphic imaging of brain; Alzheimer*s diagnosis | THE UNIVERSITY OF MICHIGAN (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | SLC18A3 248/4885CYP2D6 548/4885TSHR 599/4885 |
| US-20090005576-A1 | Production Method of Optically Active Cyclohexane Ether Compounds | DHPS, CYP8B1, CYP51A1 | SLC18A3 3557/4885CYP2D6 43/4885TSHR 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.